Literature DB >> 1773946

Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus.

M Miros1, P Kerlin, N Walker.   

Abstract

Columnar lined oesophagus (Barrett's oesophagus) carries a risk for the development of adenocarcinoma. Epithelial dysplasia appears to be a precursor but the utility of this marker for predicting subsequent adenocarcinoma is unsettled. We therefore prospectively studied 81 patients with histologically proven columnar epithelium of at least the distal 3 cm of the tubular oesophagus with regular endoscopic biopsies for a total of 289.2 patient years (mean 3.6 years, range 0.5-8). Twenty three patients (28%) had epithelial dysplasia detected during follow up. Both patients with persistent high grade dysplasia present on initial biopsies developed adenocarcinoma after 2.6-4.5 years, despite the absence of gross macroscopic change. The initial single layer pleomorphic high grade dysplasia in one patient regressed to low grade dysplasia which has persisted for 1.5 years. Of 10 patients with initial low grade dysplasia, one progressed to adenocarcinoma in 4.3 years. The low grade dysplasia persisted unchanged in seven patients for 1.5-7 years and appears to have regressed in two patients after three to five years. Ten patients developed low grade dysplasia during the surveillance period. This has persisted unchanged in six patients from 0.5-5 years, regressed in three for 0.5-5 years and has appeared after the first yearly biopsy in one patient. No patient without dysplasia has developed adenocarcinoma. The incidence of adenocarcinoma in Barrett's oesophagus in this study is one case per 96 patient years. This is 61 times (95% confidence limits 12-176) the age adjusted incidence of oesophageal cancer in Australia. Persistent high grade dysplasia appears to be a sensitive indicator for the development of subsequent adenocarcinoma.

Entities:  

Mesh:

Year:  1991        PMID: 1773946      PMCID: PMC1379239          DOI: 10.1136/gut.32.12.1441

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus.

Authors:  B J Reid; R C Haggitt; C E Rubin; G Roth; C M Surawicz; G Van Belle; K Lewin; W M Weinstein; D A Antonioli; H Goldman
Journal:  Hum Pathol       Date:  1988-02       Impact factor: 3.466

2.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

Review 3.  Barrett's esophagus and adenocarcinoma.

Authors:  B J Reid; W M Weinstein
Journal:  Annu Rev Med       Date:  1987       Impact factor: 13.739

4.  Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium.

Authors:  D S Levine; B J Reid; R C Haggitt; C E Rubin; P S Rabinovitch
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

5.  Barrett's esophagus: development of dysplasia and adenocarcinoma.

Authors:  W Hameeteman; G N Tytgat; H J Houthoff; J G van den Tweel
Journal:  Gastroenterology       Date:  1989-05       Impact factor: 22.682

6.  Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients.

Authors:  R G Lee
Journal:  Am J Surg Pathol       Date:  1985-12       Impact factor: 6.394

7.  Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus.

Authors:  C S Robertson; J F Mayberry; D A Nicholson; P D James; M Atkinson
Journal:  Br J Surg       Date:  1988-08       Impact factor: 6.939

8.  Adenocarcinoma in Barrett's oesophagus: an overrated risk.

Authors:  A H Van der Veen; J Dees; J D Blankensteijn; M Van Blankenstein
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

9.  Value of DNA image cytometry in the prediction of malignant change in Barrett's oesophagus.

Authors:  P D James; M Atkinson
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

10.  The cost of surveillance for adenocarcinoma complicating Barrett's esophagus.

Authors:  E Achkar; W Carey
Journal:  Am J Gastroenterol       Date:  1988-03       Impact factor: 10.864

View more
  64 in total

1.  Guidelines for the management of oesophageal and gastric cancer.

Authors:  W H Allum; S M Griffin; A Watson; D Colin-Jones
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

2.  Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma.

Authors:  J W van Sandick; J J van Lanschot; B W Kuiken; G N Tytgat; G J Offerhaus; H Obertop
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

3.  Time gated fluorescence spectroscopy in Barrett's oesophagus.

Authors:  M-A E J Ortner; B Ebert; E Hein; K Zumbusch; D Nolte; U Sukowski; J Weber-Eibel; B Fleige; M Dietel; M Stolte; G Oberhuber; R Porschen; B Klump; H Hörtnagl; H Lochs; H Rinneberg
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

4.  Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy?

Authors:  M S Dar; J R Goldblum; T W Rice; G W Falk
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

Review 5.  Surveillance in Barrett's oesophagus: a personal view.

Authors:  K K Basu; J S de Caestecker
Journal:  Postgrad Med J       Date:  2002-05       Impact factor: 2.401

6.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

7.  The cost effectiveness of radiofrequency ablation for Barrett's esophagus.

Authors:  Chin Hur; Sung Eun Choi; Joel H Rubenstein; Chung Yin Kong; Norman S Nishioka; Dawn T Provenzale; John M Inadomi
Journal:  Gastroenterology       Date:  2012-05-21       Impact factor: 22.682

Review 8.  Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.

Authors:  Kavel Visrodia; Siddharth Singh; Rajesh Krishnamoorthi; David A Ahlquist; Kenneth K Wang; Prasad G Iyer; David A Katzka
Journal:  Gastroenterology       Date:  2015-11-24       Impact factor: 22.682

9.  Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus.

Authors:  Ganapathy A Prasad; Kenneth K Wang; Navtej S Buttar; Louis-Michel Wongkeesong; Kausilia K Krishnadath; Francis C Nichols; Lori S Lutzke; Lynn S Borkenhagen
Journal:  Gastroenterology       Date:  2007-02-07       Impact factor: 22.682

10.  Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.

Authors:  M Solaymani-Dodaran; R F A Logan; J West; T Card; C Coupland
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.